http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110151767-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f348598b98b209c66c6d4084916d730 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 |
| filingDate | 2019-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c2c4331f653609b16ba68b0709e52a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39052bd4b1ecc75a80ce9a716960ca77 |
| publicationDate | 2019-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110151767-A |
| titleOfInvention | Application of GNF-7 in the preparation of medicine for treating influenza virus infection |
| abstract | The invention discloses the application of GNF-7 in preparing a medicine for treating influenza virus infection. The applicant detected the toxicity of GNF-7 to cells on the human monocyte cell line U937, and then determined the effect of GNF-7 on IL-8, IP-10 in the U937 cell line within the concentration range of no toxicity or low toxicity. As well as the secretion inhibition of MCP-1, three important inflammatory factors, the results show that this small molecule compound has significant anti-inflammatory activity in a dose-dependent manner. In a lethal mouse influenza infection model, treatment of infected mice with GNF-7 can effectively reduce the concentration of inflammatory factors in the lung washes of infected mice, delay the rate of weight loss in mice, and improve mouse survival. Therefore, GNF-7 disclosed in the present invention is a new type of anti-inflammatory drug for influenza, which has the advantages of good safety, high selectivity index, and effective animal model experiments, etc., and can be used for the development of drugs for the treatment of influenza virus infection. application prospects. |
| priorityDate | 2019-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 396.